-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, IkEkixN8QlUT52ePKb4P4OZIaX2G2Rr9D3swCHWxsYiWTCHDiogk4O4z5mkrp0ln nZRRjrt7fgOpexF6q6k7XQ== 0000893220-98-001019.txt : 19980521 0000893220-98-001019.hdr.sgml : 19980521 ACCESSION NUMBER: 0000893220-98-001019 CONFORMED SUBMISSION TYPE: SC 13D PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 19980520 SROS: NONE SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: CADUS PHARMACEUTICAL CORP CENTRAL INDEX KEY: 0000911148 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 133660391 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D SEC ACT: SEC FILE NUMBER: 005-46485 FILM NUMBER: 98629130 BUSINESS ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591-6705 BUSINESS PHONE: 9143453344 MAIL ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591-6705 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: SMITHKLINE BEECHAM CORP CENTRAL INDEX KEY: 0000091283 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 231099050 STATE OF INCORPORATION: PA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D BUSINESS ADDRESS: STREET 1: ONE FRANKLIN PLZ STREET 2: P O BOX 7929 CITY: PHILADELPHIA STATE: PA ZIP: 19101 BUSINESS PHONE: 2157514000 MAIL ADDRESS: STREET 1: ONE FRANKLIN PLZ STREET 2: PO BOX 7929 CITY: PHILADELPHIA STATE: PA ZIP: 19101 SC 13D 1 SCHEDULE 13D / CADUS PHARMACEUTICAL CORPORATION 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 Cadus Pharmaceutical Corporation - -------------------------------------------------------------------------------- (Name of Issuer) Common Stock, $.01 Par Value - -------------------------------------------------------------------------------- (Title of Class of Securities) 127639-10-2 - -------------------------------------------------------------------------------- (CUSIP Number) Donald F. Parman, SmithKline Beecham Corporation One Franklin Plaza, Philadelphia, PA 19102 Telephone 215-751-7633 - -------------------------------------------------------------------------------- (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) May 15, 1998 - -------------------------------------------------------------------------------- (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4), check the following box / /. Check the following box if a fee is being paid with the statement / /. (A fee is not required only if the reporting person: (1) has a previous statement on file reporting beneficial ownership of more than five percent of the class of securities described in Item 1; and (2) has filed no amendment subsequent thereto reporting beneficial ownership of five percent or less of such class.) (See Rule 13d-7.) Note: Six copies of this statement, including all exhibits, should be filed with the Commission. See Rule 13d-1(a) for other parties to whom copies are to be sent. *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). 2 SCHEDULE 13D CUSIP NO. 127639-10-2 PAGE 2 OF 7 PAGES - -------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON SmithKline Beecham plc - ------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) /x/ (b) / / - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS* WC - -------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E) / / - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION England - -------------------------------------------------------------------------------- 7 SOLE VOTING POWER NUMBER OF SHARES 330,481 BENEFICIALLY ----------------------------------------------------------------- OWNED BY 8 SHARED VOTING POWER EACH REPORTING PERSON ----------------------------------------------------------------- WITH 9 SOLE DISPOSITIVE POWER 330,481 ----------------------------------------------------------------- 10 SHARED DISPOSITIVE POWER - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 330,481 - -------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* / / - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 2.53% - -------------------------------------------------------------------------------- b14 TYPE OF REPORTING PERSON* - -------------------------------------------------------------------------------- 3 SCHEDULE 13D CUSIP NO. 127639-10-2 PAGE 3 OF 7 PAGES - -------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON SmithKline Beecham Corporation - ------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) /x/ (b) / / - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 SOURCE OF FUNDS* WC - -------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E) / / - -------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION Pennsylvania - -------------------------------------------------------------------------------- 7 SOLE VOTING POWER NUMBER OF SHARES 330,481 BENEFICIALLY ----------------------------------------------------------------- OWNED BY 8 SHARED VOTING POWER EACH REPORTING PERSON ----------------------------------------------------------------- WITH 9 SOLE DISPOSITIVE POWER 330,481 ----------------------------------------------------------------- 10 SHARED DISPOSITIVE POWER - -------------------------------------------------------------------------------- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 330,481 - -------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* / / - -------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 2.53% - -------------------------------------------------------------------------------- b14 TYPE OF REPORTING PERSON* - -------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT! 4 Page 4 of 7 Pages Item 1. Security and Issuer. Common Stock, $.01 Par Value Cadus Pharmaceutical Corporation 777 Old Saw Mill River Road Tarrytown, NY 10591-6705 Item 2. Identity and Background. (a) SmithKline Beecham plc ("SBplc"), a company organized under the laws of England, discovers, develops, manufactures and markets pharmaceuticals, vaccines, over-the-counter medicines and health-related products, and provides healthcare services including clinical laboratory testing, disease management, and pharmaceutical benefit management. SmithKline Beecham Corporation ("SBCorp"), a company organized under the laws of Pennsylvania, discovers, develops, manufactures and markets pharmaceuticals, vaccines, over-the-counter medicines and health-related products, and provides healthcare services including clinical laboratory testing, disease management, and pharmaceutical benefit management. Collectively, SBplc and SBCorp are sometimes referred to as the "Group". (b) The principal business address for SBplc is: New Horizons Court Brentford Middlesex England TW8 9EP The principal business address for SBCorp is: One Franklin Plaza Philadelphia, Pennsylvania 19102 (c) Information concerning the Group is set forth in response to Item 2(a) above. (d) During the last five years, the Group has not been convicted in a criminal proceeding, excluding traffic violations or similar misdemeanors. (e) During the last five years the Group was not a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result thereof subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to Federal or State securities laws or finding any violation with respect to such laws. (f) Not applicable. Item 3. Source and Amount of Funds or Other Consideration. Source of Funds: Working Capital Consideration: $5,000,000 Item 4. Purpose of Transaction. All of the securities acquired have been purchased for investment purposes. The Group intends to review from time to time the business affairs and financial position of the Issuer. Based on such evaluation and review, as well as general economic and industry conditions existing at the time and the Group's own financial plans, the Group may consider from time to time various alternative courses of action. Such actions may include the acquisition of additional shares through open market purchases, privately negotiated transactions or otherwise. Alternatively, such actions may involve the sale of all or a portion of the shares in the open market, in privately negotiated transactions, through public offering or otherwise. 5 Page 5 of 7 Pages Item 5. Interest in Securities of the Issuer. (a) Amount and Percent Beneficially Owned Reporting Person No. of Shares Percent SBplc 330,481 2.53% SBCorp 330,481 2.53% ______ (b) The respective members of the Group have sole power to vote and to dispose of all of the shares of Common Stock identified in subparagraph (a) above. (c) Pursuant to the February 25, 1997 Stock Purchase Agreement (as filed with the Issuer's Current Report on Form 8-K dated March 7, 1997, the "Stock Purchase Agreement"), Issuer exercised its option to sell 660,962 shares of Common Stock to the Group for an aggregate price of $5.0 million. Under the Stock Purchase Agreement if certain scientific objectives are met, Issuer has a further option to sell to the Group additional Common stock valued at $5.0 million at the-then-market price per share. That agreement also provides that the Group may elect to purchase additional Common Stock in connection with certain milestone payments pursuant to a research collaboration and license agreement between the Issuer and the Group. Issuer also granted certain registration rights with respect to shares of Common stock which the Group may purchase pursuant to the Stock Purchase Agreement. (d) Not applicable (e) Not applicable Item 6. Contracts, Arrangements, Understandings or Relationship with respect to Securities of the Issuer. See Item 5(c) above. Item 7. Materials to be Filed as Exhibits. Exhibit 1. Joint Filing Agreement dated as of May 19, 1998. 6 Page 6 of 7 Pages SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in the Statement is true, correct and complete. DATED: May 19, 1998 SMITHKLINE BEECHAM CORPORATION By: /s/Donald F. Parman -------------------------- Donald F. Parman Secretary 7 Page 7 of 7 Pages EXHIBIT 1 The undersigned hereby agree, pursuant to Rule 13d-1(f) (1) under Section 13(d) of the Securities Exchange Act of 1934, as amended, that (1) they shall cause a single Schedule 13D to be filed on behalf of both parties in respect of their ownership interests in the Common Stock of Cadus Pharmaceutical Corporation and (2) SmithKline Beecham Corporation shall be authorized to sign said Schedule 13D and any amendments thereto on behalf of both members of the Group. SMITHKLINE BEECHAM PLC By: /s/ Alison Dillon ----------------------- Alison Dillon Deputy Secretary SMITHKLINE BEECHAM CORPORATION By: /s/ Donald F. Parman ----------------------- Donald F. Parman Secretary Dated: May 19, 1998 -----END PRIVACY-ENHANCED MESSAGE-----